65 results about "Influenza (flu)" patented technology

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The collapsible saddle sleeper allows a person (e.g., adults or children) to collapse and transport the sleeper to any desired location to allow sleep in an angled position on their stomach (e.g., upper torso) and head in a straddle, sitting-like position, which helps reduce a variety of symptoms that are tied to specific medical conditions. In one example, the angled position may help a person to reduce and / or eliminate congestion and / or coughing while attempting to sleep when it's due to a common cold, flu or disease.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

The application discloses a recombinant nanobody against swine influenza virus of H1N1 subtype, and a preparation method and application thereof, and belongs to the field of biological medicines. A VHH sequence of the nanobody against swine influenza virus of H1N1 subtype is screened from a nanobody bacterial library of an immunized llama, the VHH sequence is directionally cloned into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, and the recombinant eukaryotic expression plasmid is transformed into a Pichia pastoris expression system to screen an expression engineering strain, and the recombinant nanobody is obtained after induction culture of the expression engineering strain. It is proved by in-vitro and in-vivo experiments that the recombinant nanobody developed in the application can neutralize CA / 04 and has a remarkable therapeutic effect. Therefore, the neutralizing nanobody provided in the application has considerable potential in treating CA / 04. The findings will provide experimental data for developing nanobody preparations against swine influenza virus of H1 subtype and provide a new strategy for preventing and controlling swine influenza.

The invention relates to a quinoline triazole compound and application thereof. The quinoline triazole compound has the structural characteristics as shown in formula I, and can effectively treat diseases caused by respiratory viruses such as influenza.

The invention uses ex vivo human airway cultures to assess the transmissibility and replication ability of influenza and coronavirus strains. By comparing the pandemic influenza A H1N1 and the highly pathogenic influenza A H5N1 as reference virus strains, the spreading risks of various viruses are evaluated and classified. In addition, an in vitro model is used to assess the degree of alveolar fluid clearance (AFC) impairment caused by the virus as an indicator of the severity of the disease. The research reveals the relevance among the virus replication ability, human transmission, AFC damage degree and clinical disease severity of different influenza and coronavirus strains in bronchus.

The invention relates to an application of a composition of seven probiotics in preparation of an anti-influenza virus probiotic agent. The bacterial strains in the probiotic composition comprise a combination of a streptococcus thermophilus CT-02 bacterial strain, a bifidobacterium animalis subsp. Lactis C-2 bacterial strain, a bifidobacterium longum subsp. Infantis C-3 bacterial strain, a lactobacillus delbrueckii subsp. Bulgaricus CB-01 bacterial strain, a lactobacillus acidophilus CL-01 bacterial strain, a lactobacillus paracasei CL-02 bacterial strain and a lactobacillus rhamnosus CL-03 bacterial strain. New application of the probiotic composition is developed, a research basis is provided for wide application of the probiotic composition, meanwhile, a brand-new strategy for preventing, relieving or treating influenza is also developed, it is found that the probiotic composition has a very remarkable effect in the aspect of relieving related symptoms caused by the influenza, and the probiotic composition has a good application prospect. Specifically, related symptoms such as respiratory system infection, body temperature imbalance, weight loss and vision weakening caused by influenza virus infection are obviously improved.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention relates to an anti-influenza compound as well as a preparation method and application thereof, and the anti-influenza compound has a structure as shown in formula (I): (I) wherein X1 is CR3 or N; x2 is CR4 or N; z is CR5 or N; y1 is CR6 or N; y2 is CR7 or N; y3 is CR8 or N; w is-NH-or-N = CH-; in the formula, R1 is-R < 9 >-COO < 10 >,-(CR < 122 >) < n >-R < 11 >-(CR < 122 >) < n >-O-H,-(CR < 122 >) < m >-O-H,-(CR < 122 >) < h >-COO < 10 > or-R < 11 >-CONR < 13 >-R < 14 >. The compound provided by the invention has strong inhibitory activity on influenza virus, and is subjected to in-vivo antiviral activity test, action mechanism analysis and pharmacokinetic characteristic evaluation at the same time.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.

The invention discloses a recombinant nano antibody for resisting H1N1 subtype A swine influenza virus as well as a preparation method and application thereof, and belongs to the field of biological medicines. The preparation method comprises the following steps: screening a VHH sequence for resisting an A H1N1 subtype swine influenza virus from a nano antibody bacterial library of an immune alpaca, directionally cloning the VHH sequence into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, transforming the recombinant eukaryotic expression plasmid into a pichia pastoris expression system to screen and express an engineering strain, and carrying out induced culture on the engineering strain to obtain the recombinant nano antibody. In-vitro and in-vivo experiments prove that the recombinant nano antibody developed by the invention can neutralize CA / 04 and shows a remarkable treatment effect. Therefore, the neutralizing nano antibody provided by the invention has great potential in the aspect of treatment of CA / 04. The discovery provides test data for research and development of anti-H1 subtype swine influenza virus nano antibody preparations, and provides a new strategy for prevention and control of swine influenza.

To provide a prophylactic and therapeutic agent for viral respiratory infectious diseases comprising a new component.SOLUTION: The features of the present invention for solving the above problems are as follows. 1. A prophylactic or therapeutic agent for viral respiratory infection, comprising glucosylceramide and / or glucosylceramide as an active ingredient. (2) A prophylactic or therapeutic agent for viral respiratory infections, which comprises β - sitosterol glycoside as an active ingredient. (3) The prophylactic and therapeutic agent for viral respiratory infection according to (1) or (2) above, wherein the viral respiratory infection is influenza.SELECTED DRAWING: None

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

The invention provides a combined medicine composition for treating brain glioma and application. The medicine composition comprises a copper ion carrier and a targeted NEU1 anti-influenza medicine. According to the combined medicine composition, an effective medicine combination strategy is provided for treatment of the brain glioma, and the combined medicine composition comprises a copper ion carrier, namely the illicit and an anti-influenza medicine, namely the oseltamivir. According to the invention, the condition that the combination of the ilismos and the oseltamivir has a synergistic effect on the treatment of the brain glioma is found for the first time.

The application relates to application of dihydroergotamine mesylate in preparation of anti-influenza virus drugs and belongs to the technical field of medicines. The application provides application of dihydroergotamine mesylate in preparation of anti-influenza virus drugs. The dihydroergotamine mesylate can play a role in an early replication stage after influenza virus enters a host cell, can inhibit synthesis of influenza virus nucleic acid, can significantly improve lung symptoms caused by influenza A, reduces virus titer in lung tissues, has good cell safety, biological safety and effectiveness, and has a good anti-virus application prospect.

COVID-19 and many other infectious diseases like Flu can spread through by touch. Tennis player exchange the same balls multiple times during the practice or game. For student's safety schools and colleges currently sanitize the balls manually which is a tedious and time taking job. This invention sanitizes the bunch of tennis balls in one go with the push of a buttons and a Knob which control the speed of motor vibration.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention relates to the field of biological medicine, and particularly discloses an RSV-influenza combined vaccine and application thereof. The RSV-influenza combined vaccine comprises a respiratory syncytial virus mRNA vaccine and an influenza vaccine, the respiratory syncytial virus mRNA vaccine also comprises lipid nanoparticles, and the mRNA is loaded in the lipid nanoparticles. The RSV-influenza combined vaccine is used for preventing infection of various respiratory viruses (RSV virus and influenza virus), and the LNP adjuvant of the RSV mRNA vaccine can greatly increase the immune response of the influenza vaccine and enhance the protection efficiency of the influenza vaccine in immunocompromised people.

The present invention relates to an imidazopyridine derivative and a pharmaceutical composition comprising same as an active ingredient and, more particularly, to an imidazopyridine derivative that inhibits protein kinase activity and as such, can be used for preventing or treating cancer, neurodegenerative disease, non-alcoholic fatty liver disease, influenza, etc., and a pharmaceutical composition comprising same as an active ingredient.

The application belongs to the technical field of traditional Chinese medicines, and discloses a fingerprint spectrum detection method of Shuanghuanglian traditional Chinese medicine composition and application thereof. The fingerprint spectrum detection method is as follows: high performance liquid chromatography is used to analyze test sample solution and control sample solution; and a fingerprint spectrum is obtained by processing the color spectrum by using a fingerprint spectrum software; in the liquid chromatography analysis, gradient elution is performed by using a mobile phase, and the mobile phase is as follows: the A phase includes phosphoric acid aqueous solution, and the B phase includes acetonitrile and methanol. The fingerprint spectrum detection method can calibrate at least 22 chromatographic peaks under different detection wavelengths, and identify 10 kinds of effective components such as forsythia ester glycoside E, chlorogenic acid and coffee acid, and simultaneously perform quantitative analysis on multiple components; the fingerprint spectrum detection method can make each batch of medicines have stable and reliable therapeutic effects. The Shuanghuanglian traditional Chinese medicine composition screened by the quality control and having specific active component content characteristics can be used for preparing medicines for reducing susceptibility to influenza.

To provide a composition for treating and / or preventing influenza, food and drink, and feed, which are excellent in safety as well as preventive effect and treatment effect.SOLUTION: The present disclosure provides a composition for treating and / or preventing influenza containing a retinoid compound as an active ingredient.SELECTED DRAWING: Figure 2

A topical composition comprising a nanonised L-glutathione and cyclodextrin complex, together with ascorbic acid in a weight ratio of glutathione to ascorbic acid from 7:1 to 15:1 and from 1:1 to 1:15 and a further compound comprising dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate or acetyl-L-cysteine, which composition is topically administered for treating the symptoms of viral infection including COVID-19 and influenza, and for treating herpes simplex, herpes zoster, post herpetic neuralgia, genital herpes, alcohol detoxification, high triglycerides, age or liver spots and lupus.

The present disclosure relates to compositions comprising RNA molecules encoding influenza-derived antigens, where the RNA may be formulated in lipid nanoparticles (LNPs), and the compositions further comprise a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or an RNA molecule encoding an antigen derived from RSV, where the RSV RNA may be formulated in LNPs. The present disclosure further relates to the use of RNA molecules, RNA-LNPs, and compositions for the prevention of influenza and RSV infection-induced illnesses.

The invention belongs to the field of medicines, and discloses a ganoderma triterpenic acid compound, a preparation method thereof and application of the ganoderma triterpenic acid compound in prevention and treatment of influenza viruses. The ganoderma triterpenic acid compound (24E)-3alpha-hydroxy-7-oxo-lanosta-8, 24-dien-26-oic acid is as shown in a formula I which is described in the specification. Experiments prove that the compound disclosed by the invention has relatively good influenza virus neuraminidase inhibitory activity, and the IC50 of the compound is 18.3 mu M. Researches show that the compound has an application prospect in further development of novel anti-influenza drugs.

The invention discloses a novel coronal virus mucosal immune vaccine based on a non-replicating vesicular stomatitis virus vector. The vaccine is delivered through a mucosal immunization way; the vaccine can be used in new crown vaccines, and can also be used in combination with other respiratory tract infection viruses such as respiratory syncytial vaccines (RSV) and influenza. At present, preparation of respiratory mucosa vaccines, especially multivalent vaccines, from replication-deficient VSV is not reported yet. According to the invention, safety and immunogenicity evaluation is carried out on the constructed VSVMT-S2P non-replicating recombinant VSV new crown vaccine in healthy narrative golden hamster and CP immunosuppression hamster models, and the VSVMT-S2P vaccine is found to be very safe in healthy animals; and the protein is highly safe in CP immunosuppressed hamsters. The VSVMT-S2P vaccine is subjected to single inoculation in the body of the narrative golden hamster through intranasal and intramuscular injection respectively, and it is proved that the VSVMT-S2P vaccine can effectively stimulate comprehensive immune response.

The present disclosure provides a set of primers and optional probes for identifying the presence of alpha-coronavirus, beta-coronavirus, SARS-CoV-2, adenovirus, chlamydia pneumoniae, influenza A, influenza B, metapneumovirus, rhinovirus / enterovirus, mycoplasma, Bordetella, parainfluenza, and respiratory syncytial virus (RSV), the present invention relates to nucleic acid probes, which may be included with a cartridge (e.g., in a kit) or in a cartridge, for automated detection of these pathogens by nucleic acid amplification. The disclosure also provides related detection methods, as well as kits, systems, and kits useful in such methods.

The invention discloses a predictive biomarker for influenza pregnant woman concurrent pneumonia, the predictive biomarker is double-negative T cell percentage or IL-2 concentration, and discloses application of the double-negative T cell percentage or IL-2 concentration as a biomarker in preparation of a diagnostic reagent for predicting influenza pregnant woman concurrent pneumonia. The kit comprises a reagent for detecting the percentage of the double-negative T cells and / or the IL-2 concentration level and is used for detecting the influenza pregnant woman concurrent pneumonia. It is found for the first time that both the percentage of double-negative T cells and the increase of the IL-2 level can independently predict pneumonia, DNT% shows the highest diagnosis accuracy (AUROC = 0.8925), when the critical value is set to be 1.66%, the sensitivity and specificity of the kit reach 90% and 91% respectively, the clinical application value of the kit as an early warning index is highlighted, the risk of influenza pregnant women complicated with pneumonia can be effectively predicted, and the kit has a good application prospect. And the population with high pneumonia risk in the influenza pregnant women is identified.